Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions reported second quarter 2026 revenue of $234.3 million, up 66% year over year, driven mainly by U.S. government medical countermeasure contracts for products such as ACAM2000 and BAT. Despite this, the company posted a GAAP net loss of $180.2 million, largely due to a $191.3 million non-cash impairment on the NARCAN asset group. Non-GAAP results were much stronger, with adjusted net income of $30.9 million and adjusted EBITDA of $96.5 million, yielding a 41% adjusted EBITDA margin.
Management launched a restructuring plan that will cut approximately 93 employees, eliminate about 21 vacant roles, close wet laboratories in Gaithersburg, and is expected to generate about $40 million in annualized savings, while incurring $10–$11.5 million of charges mainly in the second half of 2026. The role of Chief Medical Officer, Head of R&D is being eliminated and Simon Lowry will depart, while Stephanie Duatschek becomes Executive Vice President, Chief Growth Officer. Full-year 2026 guidance was reduced to revenue of $645–$675 million, a net loss of $(245)–$(225) million, and adjusted EBITDA of $130–$150 million, reflecting pressures in the naloxone business and the impairment charge.
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 2,540,945 shares of Emergent BioSolutions Inc. common stock, representing 4.92% of the class as of June 30, 2026. Vanguard has sole voting power over 342,106 shares and sole dispositive power over all 2,540,945 shares, with no shared voting or dispositive power. The holdings include securities held by various Vanguard funds and managed accounts over which these entities exercise voting and/or dispositive authority, and no other single person’s interest in these securities exceeds 5%.
BlackRock, Inc. reports beneficial ownership of 4,651,339 shares of Emergent BioSolutions Inc. common stock, representing 9.0% of the class as of June 30, 2026. BlackRock has sole voting power over 4,588,703 shares and sole dispositive power over 4,651,339 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds from these shares, but no single person holds more than five percent of Emergent’s outstanding common stock through these positions.
Emergent BioSolutions Inc. reported an insider stock sale by senior vice president Paul Anthony Williams. On July 1, 2026, he executed an open-market sale of 3,000 shares of common stock at a weighted average price of $8.40 per share, with individual sale prices ranging from $8.31 to $8.46. The transaction was made under a pre-arranged trading plan adopted on November 14, 2025 intended to comply with Rule 10b5-1. Following this sale, Williams directly holds 159,098 shares of Emergent BioSolutions common stock.
Emergent BioSolutions entered a contract modification valued at $52.7 million with the U.S. Administration for Strategic Preparedness and Response to supply its ACAM2000 smallpox and mpox vaccine, related ancillaries, and diluent replacement lots under an existing 10-year contract.
The modification, designated Option Year 7, calls for delivery of ACAM2000 doses and ancillaries in June 2026, with any remaining diluent balance due by December 2026. The company highlights this award alongside recent approvals of ACAM2000 for high-risk individuals in Saudi Arabia and an expanded indication in Singapore.
Emergent BioSolutions Inc. senior vice president of the Products Business, Paul Anthony Williams, reported a routine tax-related share disposition. On the vesting and settlement of restricted stock units, 694 shares of common stock were withheld at $8.00 per share to cover associated tax obligations.
Following this withholding, Williams directly holds 162,098 shares of Emergent BioSolutions common stock. The transaction was not an open-market sale but a standard payment of tax liability using shares received from equity compensation.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported a routine tax-related share disposition. On the reported date, 3,964 shares of common stock were withheld at $8.00 per share to cover taxes tied to the vesting and settlement of restricted stock units, rather than being sold on the open market. After this withholding, Lindahl directly held 374,083 shares of common stock, indicating he retains a substantial equity position in the company.
Emergent BioSolutions Inc. executive Coleen Glessner reported a routine tax-related share disposition. On the vesting and settlement of restricted stock units, 2,018 shares of common stock were withheld to cover associated taxes at an indicated value of $8.00 per share. After this withholding, she directly holds 202,201 shares of Emergent BioSolutions common stock, so the filing reflects a compensation and tax event rather than an open-market trade.
Emergent BioSolutions Inc. Senior Vice President of Bioservices William Hartzel reported a routine tax-related share disposition. On June 8, 2026, 1,741 shares of common stock were withheld at $8.00 per share to cover taxes from the vesting and settlement of restricted stock units. After this withholding, Hartzel directly held 185,558 shares of Emergent BioSolutions common stock. This was not an open-market sale but an automatic tax-withholding mechanism tied to equity compensation.